CN101516394B - 制备抗耐药性抗原的活性抗体的方法、所述方法获得的抗体及其用途 - Google Patents

制备抗耐药性抗原的活性抗体的方法、所述方法获得的抗体及其用途 Download PDF

Info

Publication number
CN101516394B
CN101516394B CN200780035523.8A CN200780035523A CN101516394B CN 101516394 B CN101516394 B CN 101516394B CN 200780035523 A CN200780035523 A CN 200780035523A CN 101516394 B CN101516394 B CN 101516394B
Authority
CN
China
Prior art keywords
tumor
antibody
antibodies
resistant
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780035523.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN101516394A (zh
Inventor
L·哥彻
A·茹阿诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of CN101516394A publication Critical patent/CN101516394A/zh
Application granted granted Critical
Publication of CN101516394B publication Critical patent/CN101516394B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200780035523.8A 2006-09-28 2007-09-27 制备抗耐药性抗原的活性抗体的方法、所述方法获得的抗体及其用途 Expired - Fee Related CN101516394B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0608514A FR2906533B1 (fr) 2006-09-28 2006-09-28 Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
FR06/08514 2006-09-28
PCT/EP2007/060243 WO2008046724A1 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses

Publications (2)

Publication Number Publication Date
CN101516394A CN101516394A (zh) 2009-08-26
CN101516394B true CN101516394B (zh) 2014-07-30

Family

ID=38164542

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780035523.8A Expired - Fee Related CN101516394B (zh) 2006-09-28 2007-09-27 制备抗耐药性抗原的活性抗体的方法、所述方法获得的抗体及其用途

Country Status (21)

Country Link
US (2) US8241646B2 (enExample)
EP (4) EP2491945B9 (enExample)
JP (1) JP5774276B2 (enExample)
KR (1) KR101504770B1 (enExample)
CN (1) CN101516394B (enExample)
AR (1) AR063061A1 (enExample)
AU (1) AU2007312437C1 (enExample)
BR (1) BRPI0717246A2 (enExample)
CA (1) CA2663561A1 (enExample)
FR (1) FR2906533B1 (enExample)
IL (1) IL197790A (enExample)
MA (1) MA30954B1 (enExample)
MX (1) MX2009003245A (enExample)
NO (1) NO20091613L (enExample)
NZ (1) NZ576420A (enExample)
RU (1) RU2515904C2 (enExample)
TN (1) TN2009000102A1 (enExample)
TW (1) TWI516276B (enExample)
UA (1) UA102812C2 (enExample)
WO (1) WO2008046724A1 (enExample)
ZA (1) ZA200902697B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
WO2011004899A1 (en) * 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
US20120282211A1 (en) * 2009-11-24 2012-11-08 Carnegie Mellon University Antibodies and conjugates for modulators of angiogenesis
EP3165538A1 (en) 2010-11-03 2017-05-10 Argen-X Nv Anti c-met antibodies
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
BR112015022123B1 (pt) * 2013-03-15 2022-08-09 Intrinsic Lifesciences, Llc Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit
CN106794194A (zh) * 2014-06-30 2017-05-31 中央研究院 用于癌症治疗的介白素‑17受体b（il‑17rb）及其配体il‑17b之拮抗剂
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
TWI716400B (zh) * 2015-04-27 2021-01-21 法商皮爾法伯製藥公司 新穎的igf-1r抗體及其用於癌症診斷之用途（二）
AR104413A1 (es) * 2015-04-27 2017-07-19 Pf Medicament Anticuerpo de igf-1r y su utilización para diagnosticar cáncer
JP6976241B2 (ja) * 2015-08-14 2021-12-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ｔｉｇｉｔ抗体
JP6952028B2 (ja) * 2015-09-29 2021-10-20 シャンハイ チャンジアン バイオテクノロジー カンパニー リミテッド Ｐｄ−１抗体およびその使用
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
WO2025111382A2 (en) * 2023-11-21 2025-05-30 Board Of Regents, The University Of Texas System Anti-lamp5 antibodies, engineered immune cells expressing anti-lamp5 antibodies, and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214640A2 (en) * 1985-09-11 1987-03-18 Japanese Foundation For Cancer Research Monoclonal antibody in relation to drug-resistant cancers and production thereof
US5503984A (en) * 1993-04-13 1996-04-02 Health Research, Inc. Hybridoma producing monoclonal antibody F4 which specifically binds to multidrug resistant P-glycoprotein and assays for detection of P-glycoprotein

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
KR950700061A (ko) * 1992-02-06 1995-01-16 스티븐 엘. 네스비트 테트라아릴에틸렌에 의한 다중 약물 내성의 역전(reversal of multi -drug resistance by tetraarylethylenes)
IT1257893B (it) * 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1999066027A1 (en) * 1998-06-15 1999-12-23 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
EP1806364B1 (fr) 2002-01-18 2013-07-31 Pierre Fabre Medicament Nouveaux anticorps anti-igf-ir et leurs applications
WO2004026293A2 (en) 2002-09-20 2004-04-01 Wyeth Holdings Corporation Hemiasterlin derivatives for treating resistant tumors
US20050142609A1 (en) * 2003-10-08 2005-06-30 Ebioscience Native immunoglobulin binding reagents and methods for making and using same
PT1720540E (pt) 2004-02-18 2008-09-10 Gpc Biotech Ag Métodos de tratamento de tumores resistentes ou refractários
EP1742060A1 (en) * 2005-01-24 2007-01-10 DIGILAB BioVisioN GmbH TIF1-beta peptides and nucleic acids for diagnosis and therapy of cancer and colorectal cancerous disorders.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214640A2 (en) * 1985-09-11 1987-03-18 Japanese Foundation For Cancer Research Monoclonal antibody in relation to drug-resistant cancers and production thereof
US5503984A (en) * 1993-04-13 1996-04-02 Health Research, Inc. Hybridoma producing monoclonal antibody F4 which specifically binds to multidrug resistant P-glycoprotein and assays for detection of P-glycoprotein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Vermeercsh Willians C., et al..Substractive Immuinzation Techinques for the Production of Monoclonal Antibodies to Rare Antigens.《Biotechniques》.1992,第12卷(第6期), *

Also Published As

Publication number Publication date
TW200822934A (en) 2008-06-01
EP2497491B1 (en) 2017-03-01
BRPI0717246A2 (pt) 2013-10-08
KR20090057469A (ko) 2009-06-05
AR063061A1 (es) 2008-12-23
KR101504770B1 (ko) 2015-03-20
IL197790A (en) 2016-10-31
JP2010504743A (ja) 2010-02-18
IL197790A0 (en) 2011-08-01
EP2491945B9 (en) 2017-03-08
US8241646B2 (en) 2012-08-14
EP2494984B1 (en) 2017-01-04
EP2491945B1 (en) 2016-12-07
FR2906533A1 (fr) 2008-04-04
AU2007312437C1 (en) 2014-04-10
US20130028835A1 (en) 2013-01-31
EP2497491A1 (en) 2012-09-12
UA102812C2 (ru) 2013-08-27
WO2008046724A1 (en) 2008-04-24
CA2663561A1 (en) 2008-04-24
EP2494984A1 (en) 2012-09-05
CN101516394A (zh) 2009-08-26
AU2007312437B2 (en) 2014-01-23
US20100146650A1 (en) 2010-06-10
NO20091613L (no) 2009-06-26
EP2081592A1 (en) 2009-07-29
US8808667B2 (en) 2014-08-19
ZA200902697B (en) 2010-04-28
MA30954B1 (fr) 2009-12-01
MX2009003245A (es) 2009-07-07
TN2009000102A1 (en) 2010-08-19
HK1131063A1 (en) 2010-01-15
RU2009114682A (ru) 2010-11-20
FR2906533B1 (fr) 2013-02-22
NZ576420A (en) 2012-05-25
JP5774276B2 (ja) 2015-09-09
AU2007312437A1 (en) 2008-04-24
EP2081592B1 (en) 2016-01-13
RU2515904C2 (ru) 2014-05-20
TWI516276B (zh) 2016-01-11
EP2491945A1 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
CN101516394B (zh) 制备抗耐药性抗原的活性抗体的方法、所述方法获得的抗体及其用途
CN111363041B (zh) 新型抗-pd-l1抗体
CN101535344B (zh) 新型抗增殖抗体
WO2017215585A1 (zh) 抗cd47单克隆抗体及其应用
CN113563470B (zh) 结合tigit抗原的抗体及其制备方法与应用
CN114761433B (zh) 一种抗Claudin18.2单克隆抗体、其制备方法及用途
CN110698560B (zh) 一种tpbg抗体及其制备方法、其偶联物和应用
CN108690136B (zh) 一种人源化抗tpbg抗体及其制备方法、其偶联物和应用
CN111518208B (zh) 抗cd47抗体及其应用
CN116265486A (zh) 结合人cd73的抗体、其制备方法和用途
US20250296989A1 (en) ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
HK1131063B (en) Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
CN118891287A (zh) 抗cd73的抗体及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1131063

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1131063

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140730

Termination date: 20170927